News
US-based Cardurion Pharmaceuticals has completed enrolment in two multi-centre, global Phase II CYCLE trials of the orally-administered phosphodiesterase 9 (PDE9) inhibitor, CRD-750, targeting both ...
Q2 2025 Earnings Call Transcript August 5, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $6.02, expectations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback